

June 15, 2019

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re.: Notification

Dear Sir/Madam,

We hereby inform that the manufacturing facility of Alidac Pharmaceuticals Ltd (Alidac), located at Pharmez, Ahmedabad has received an Establishment Inspection Report (EIR). Alidac is a 100% subsidiary of Cadila Healthcare Ltd.

The USFDA had conducted a Pre-Approval Inspection (PAI) for Doxorubicin Liposomal, a complex oncological injectable at Alidac, the injectable onco manufacturing facility, from 18th to 26th March, 2019. There was also a separate in-vitro BE inspection conducted by the Office of Study Integrity and Surveillance branch of the USFDA for the same product.

We request you to bring this news to the notice of the members of the exchange and the investors at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


DHAVAL N. SONI
COMPANY SECRETARY

